WuXi AppTec is closing down its contract research organization in Austin, TX, by the end of the year, a company spokesperson told Endpoints News. The move is part of its goal to “sharpen” its focus …
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffra
Madrigal Pharmaceuticals CEO Bill Sibold doesn’t seem worried about sharing the MASH market with Novo Nordisk’s blockbuster GLP-1 drug. In an interview with Endpoints News



